<DOC>
	<DOCNO>NCT02612922</DOCNO>
	<brief_summary>Trial evaluate efficacy safety nitazoxanide ( NTZ ) treatment acute uncomplicated influenza .</brief_summary>
	<brief_title>Trial Evaluate Efficacy Safety Nitazoxanide Treatment Acute Uncomplicated Influenza</brief_title>
	<detailed_description>A multicenter randomize double-blind placebo control trial design evaluate efficacy safety NTZ 600 mg administer orally twice daily five day compare placebo treatment acute uncomplicated influenza .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Nitazoxanide</mesh_term>
	<criteria>1 . Age 12 65 year 2 . Presence clinical sign and/or symptom consistent acute illness compatible influenza infection ( follow require ) : oral temperature ≥100.4°F ≥38°C ( obtain office selfmeasured within 12 hour prior screen selfmeasured , subject must also take antipyretic within 4 hour prior screen ) AND least one follow respiratory symptom ( cough , sore throat , nasal obstruction ) , AND one follow constitutional symptom ( fatigue , headache , myalgia , feverishness ) . 3 . Confirmation influenza A B infection local community one following mean : institution 's local laboratory , local public health system , national public health system , laboratory recognize national multinational influenza surveillance scheme . 4 . Onset illness 40 hour enrollment trial . Note : Time onset illness define either earlier : time temperature first measure elevate , OR time subject experienced presence least one respiratory symptom AND presence least one constitutional symptom . 5 . Willing able provide write informed consent ( include assent legal guardian 18 year age ) comply requirement protocol , include completion patient diary . 1 . Severity illness requiring anticipate require inhospital care subject define high risk complication influenza infection accord Infectious Diseases Society America ( IDSA ) guideline seasonal influenza adult child ( Committee Infectious Diseases ( CID ) 2009:48 ) current Centers Disease Control Prevention ( CDC ) criterion . Current criterion person 1265 year age risk influenza complication include ( list review update required prior initiation study least monthly study ) : Persons asthma chronic pulmonary disease , cystic fibrosis child chronic obstructive pulmonary disease adult . Persons hemodynamically significant cardiac disease . Persons immunosuppressive disorder receive immunosuppressive therapy . Human Immunodeficiency Virus ( HIV ) infect person . Persons sickle cell anemia hemoglobinopathy . Persons diseases require longterm aspirin therapy , rheumatoid arthritis Kawasaki disease . Persons chronic renal dysfunction . Persons liver disorder . Persons active cancer . Persons chronic metabolic disease , diabetes mellitus , inherit metabolic disorder mitochondrial disorder . Persons neuromuscular disorder , seizure disorder cognitive dysfunction may compromise handle respiratory secretion . Residents age nursing home longterm care institution . Persons morbidly obese ( Body Mass Index ≥40 ) . American Indians . Alaskan native . 2 . Females childbearing potential either pregnant , breastfeed sexually active without use birth control . Female subject childbearing potential sexually active must negative baseline pregnancy test must agree continue acceptable method birth control duration study 1 month posttreatment . A double barrier method , oral birth control pill administer least 2 monthly cycle prior study drug administration , intrauterine device ( IUD ) , medroxyprogesterone acetate administer intramuscularly minimum one month prior study drug administration acceptable method birth control inclusion study . Female subject consider childbearing potential unless postmenopausal ( absence menstrual bleeding 1 year 6 month laboratory confirmation hormonal status ) , hysterectomy , bilateral tubular ligation bilateral ovariectomy . 3 . Vaccination seasonal influenza August 1 , 2015 . 4 . Receipt dose nitazoxanide , oseltamivir , zanamivir , peramivir , amantadine rimantadine within 30 day prior screen . 5 . Prior treatment investigational drug therapy within 30 day prior screen . 6 . Subjects active respiratory allergy subject expect require antiallergy medication study period respiratory allergy . 7 . Known sensitivity nitazoxanide excipients comprise nitazoxanide tablet . 8 . Subjects unable take oral medication . 9 . Subject chronic kidney liver disease ( include Hepatitis A , B C ) know impaired hepatic and/or renal function . 10 . Presence preexist chronic infection undergo require medical therapy . 11 . Presence preexist illness , opinion Investigator , would place subject unreasonably increase risk participation study . 12 . Subjects , judgment Investigator , unlikely comply requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Influenza</keyword>
</DOC>